Cytori Reports Second Quarter 2015 Business and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to Cytori Reports Second Quarter 2015 Business and Financial Results
August 10, 2015 7:56 AM EDT
Roth Capital reiterated a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target to $4.00 (from $6.00), following the company's 2Q15 earnings release. EPS of $0.03 beat the consensus estimates of -$0.03. CYTX ended the quarter with $23.8 million in cash.
Analyst Joseph Pantginis... More
August 7, 2015 7:43 AM EDT
Maxim Group analyst Jason Kolbert trimmed his price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) to $5.00 (from $7.00) following Q2 results but maintained his Buy rating.
The cut comes on a greater than expected share count.
The analyst highlighted the following Quarter Progress: STAR TRIAL, OA, Incontinence and Burns
Announced the launch of its US STAR trial, which is being considered a "pivotal"...
More
August 6, 2015 4:38 PM EDT
Cytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of $0.03, $0.06 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $2.5 million.
For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.
...
More
